BIOLOGICAL MARKERS OF RECTAL CANCER NEOADJUVANT CHEMORADIOTHERAPY EFFICACY

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

Localization of the primary tumor of the colon: аre there essential differences?

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2017-12-01

Role of microsatellite instability in colon cancer

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

CHOICE OF TARGETED DRUG FOR SECOND-LINE METASTATIC COLON CANCER CHEMOTHERAPY

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-05-01

FIRST-LINE TREATMENT IN PATIENTS WITH INOPERABLE METASTATIC COLON CANCER

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

Efficacy of continuing anti-angiogenic agents in the second-line treatment for metastatic colon cancer depending on the KRAS mutation status: a meta-analysis

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2018-07-01

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

Chemotherapy of metastatic colon cancer

Por M. Yu. Fedyanin, A. А. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

ADJUVANT CHEMOTHERAPY AFTER RECTAL CANCER CHEMORADIOTHERAPY

Por M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2015-02-01

Heterogeneity and clonal evolution of colorectal cancer

Por M. Yu. Fedyanin, H. H.-M. Elsnukaeva, S. A. Tjulandin
Publicado em 2017-04-01

Colorectal cancer, screening: achievements и opportunities

Por E. A. Polyanskaya, M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin
Publicado em 2018-12-01

Effect of cancer drugs in patients with metastatic colorectal cancer in terms of mortality reduction

Por M. Yu. Fedyanin, I. A. Pokataev, O. V. Sekhina, A. A. Tryakin, S. A. Tjulandin
Publicado em 2017-12-01

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis

Por Mikhail Yu Fedyanin, Elizaveta M Polyanskaya, Alexey A Tryakin, Ilia A Pokataev, Sergei A Tjulandin
Publicado em 2019-09-01

FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis

Por M. Yu. Fedyanin, E. M. Polyanskaya, H. H.-M. Elsnukaeva, A. A. Tryakin, I. A. Pokataev, A. A. Bulanov, S. A. Tjulandin
Publicado em 2020-12-01

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer

Por M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publicado em 2020-12-01

PROGNOSTIC VALUE OF VHL GENE ALTERATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

Por D. A. Nosov, E. S. Yakovleva, M. Yu. Fedyanin, D. A. Chekini, M. N. Sinitsyna, N. A. Savelov, D. S. Mikhailenko, D. V. Zaletayev, L. N. Lyubchenko, S. A. Tjulandin
Publicado em 2011-09-01

FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study

Por M. Yu. Fedyanin, E. M. Polyanskaya, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh.-Kh. M. Elsnukaeva, A. N. Polyakov, I. V. Sagaydak, V. D. Podluzhniy, V. A. Aliev, S. S. Gordeev, D. V. Kuzmichev, Z. Z. Mamedli, S. A. Tjulandin
Publicado em 2019-11-01

Concordance between the tumor mutational status and circulating tumor DNA in patients with colorectal cancer

Por E. M. Polyanskaya, M. Yu.  Fedyanin, U. A. Boyarskikh, A. A. Kechin, E. A. Moroz, A. N. Polyakov, N. E. Kudashkin, D. V. Podluzhniy, E. A. Khrapov, I. P. Oskorobin, D. V. Shamovskaya, V. A. Aliev, Z. Z. Mamedli, A. A. Tryakin, M. L. Filipenko, S. A. Tjulandin
Publicado em 2022-04-01

Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study

Por M. Yu. Fedyanin, Kh. Kh.-M. El’sunkaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, V. A. Aliev, D. V. Kuzmichev, Z. Z. Mamedli, M. V. Chernykh, V. V. Glebovskaya, S. I. Tkachev, N. A. Kozlov, S. A. Tjulandin
Publicado em 2018-07-01

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

Por M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin
Publicado em 2021-06-01